Video

Dr. Susanibar-Adaniya on the Standard of Care for Patients With Newly Diagnosed Multiple Myeloma

Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.

Sandra P. Susanibar-Adaniya, MD, assistant professor of medicine, University of Pennsylvania, Penn Medicine, discusses the current standard of care for patients with newly diagnosed multiple myeloma.

Advances in the therapeutic landscape of multiple myeloma over the last 2 decades have provided promising results and beneficial outcomes to patients, Susanibar-Adaniya says.

Treatment for patients with newly diagnosed multiple myeloma begins with induction therapy with the goal of reducing the presence of multiple myeloma, followed by consolidation with stem cell transplantation if a patient is fit enough, Susanibar-Adaniya continues. Maintenance therapy is then utilized to preserve any response that has been obtained, and disease management is used in order to maximize the chances for patients to have a good quality of life, Susanibar-Adaniya concludes.

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS